TY - JOUR
T1 - Application of 1H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis
AU - Zabek, Adam
AU - Swierkot, Jerzy
AU - Malak, Anna
AU - Zawadzka, Iga
AU - Deja, Stanisław
AU - Bogunia-Kubik, Katarzyna
AU - Mlynarz, Piotr
N1 - Funding Information:
This work was supported in part by the Polish National Science Centre : Grant no. 2011/01/B/NZ5/05367 and by Wroclaw University of Technology S40531/Z0303 and WCB KNOW 2014–2018. The authors thank K. Gebura and L. Korman for technical assistance.
PY - 2016/1/5
Y1 - 2016/1/5
N2 - Rheumatoid arthritis is a chronic autoimmune-based inflammatory disease that leads to progressive joint degeneration, disability, and an increased risk of cardiovascular complications, which is the main cause of mortality in this population of patients. Although several biomarkers are routinely used in the management of rheumatoid arthritis, there is a high demand for novel biomarkers to further improve the early diagnosis of rheumatoid arthritis, stratification of patients, and the prediction of a better response to a specific therapy. In this study, the metabolomics approach was used to provide relevant biomarkers to improve diagnostic accuracy, define prognosis and predict and monitor treatment efficacy. The results indicated that twelve metabolites were important for the discrimination of healthy control and rheumatoid arthritis. Notably, valine, isoleucine, lactate, alanine, creatinine, GPC&&APC and histidine relative levels were lower in rheumatoid arthritis, whereas 3-hydroxyisobutyrate, acetate, NAC, acetoacetate and acetone relative levels were higher. Simultaneously, the analysis of the concentration of metabolites in rheumatoid arthritis and 3 months after induction treatment revealed that L1, 3-hydroxyisobutyrate, lysine, L5, acetoacetate, creatine, GPC. +. APC, histidine and phenylalanine were elevated in RA, whereas leucine, acetate, betaine and formate were lower. Additionally, metabolomics tools were employed to discriminate between patients with different IL-17A genotypes. Metabolomics may provide relevant biomarkers to improve diagnostic accuracy, define prognosis and predict and monitor treatment efficacy in rheumatoid arthritis.
AB - Rheumatoid arthritis is a chronic autoimmune-based inflammatory disease that leads to progressive joint degeneration, disability, and an increased risk of cardiovascular complications, which is the main cause of mortality in this population of patients. Although several biomarkers are routinely used in the management of rheumatoid arthritis, there is a high demand for novel biomarkers to further improve the early diagnosis of rheumatoid arthritis, stratification of patients, and the prediction of a better response to a specific therapy. In this study, the metabolomics approach was used to provide relevant biomarkers to improve diagnostic accuracy, define prognosis and predict and monitor treatment efficacy. The results indicated that twelve metabolites were important for the discrimination of healthy control and rheumatoid arthritis. Notably, valine, isoleucine, lactate, alanine, creatinine, GPC&&APC and histidine relative levels were lower in rheumatoid arthritis, whereas 3-hydroxyisobutyrate, acetate, NAC, acetoacetate and acetone relative levels were higher. Simultaneously, the analysis of the concentration of metabolites in rheumatoid arthritis and 3 months after induction treatment revealed that L1, 3-hydroxyisobutyrate, lysine, L5, acetoacetate, creatine, GPC. +. APC, histidine and phenylalanine were elevated in RA, whereas leucine, acetate, betaine and formate were lower. Additionally, metabolomics tools were employed to discriminate between patients with different IL-17A genotypes. Metabolomics may provide relevant biomarkers to improve diagnostic accuracy, define prognosis and predict and monitor treatment efficacy in rheumatoid arthritis.
KW - H NMR spectroscopy
KW - Metabolomics
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84944463857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944463857&partnerID=8YFLogxK
U2 - 10.1016/j.jpba.2015.10.007
DO - 10.1016/j.jpba.2015.10.007
M3 - Article
C2 - 26476882
AN - SCOPUS:84944463857
SN - 0731-7085
VL - 117
SP - 544
EP - 550
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
ER -